ESR2 and neoplasm: ERβ is the dominant ER in the mammary gland and is expressed in more than 50% of BC cases, neither depending on ERα status nor the molecular BC subtype, and is considered a tumor suppressor and partial ERα antagonist in BC and prostate cancer [21].